Inhibrx Inc
NASDAQ:INBX
Inhibrx Inc
Revenue
Inhibrx Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Inhibrx Inc
NASDAQ:INBX
|
Revenue
$1.8m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Inhibrx Inc
Revenue Breakdown
Breakdown by Geography
Inhibrx Inc
Breakdown by Segments
Inhibrx Inc
Total Revenue:
1.8m
USD
|
License Fee Revenue:
1.8m
USD
|
See Also
What is Inhibrx Inc's Revenue?
Revenue
1.8m
USD
Based on the financial report for Dec 31, 2023, Inhibrx Inc's Revenue amounts to 1.8m USD.
What is Inhibrx Inc's Revenue growth rate?
Revenue CAGR 5Y
-27%
Over the last year, the Revenue growth was -18%. The average annual Revenue growth rates for Inhibrx Inc have been -48% over the past three years , -27% over the past five years .